• Section 1: Anxiety Disorders
• Chapter 1: Cognitive-Behavioral Therapy, Imipramine, or Their Combination for Panic Disorder
• Amanda Sun and Tobias Wasser
• Chapter 2: Fluoxetine, Comprehensive Cognitive Behavioral Therapy, and Placebo in Generalized Social Phobia
• Erin Habecker and Tobias Wasser
• Section 2: Bipolar Disorder
• Chapter 3: Lithium Plus Valproate Combination Versus Monotherapy for Relapse Prevention in Bipolar I Disorder (BALANCE)
• João Paulo De Aquino and Robert Beech
• Chapter 4: Mood Stabilizer Monotherapy vs. Adjunctive Antidepressant for Bipolar Depression: The STEP-BD Trial
• João Paulo De Aquino and Robert Beech
• Chapter 5: Suicide Risk in Bipolar Disorder: Comparing Lithium, Divalproex, and Carbamazepine
• Rachel Katz and Robert Beech
• Chapter 6: The Long-term Natural History of Bipolar I Disorder
• Zachary Engler and Robert Beech
• Section 3: Child and Adolescent Disorders
• Chapter 7: The Multimodal Treatment Study of Children with Attention Deficit/Hyperactivity Disorder (MTA)
• Michael Hochman, edited by Michael H. Bloch
• Chapter 8: Adolescents with SSRI-Resistant Depression: The TORDIA Trial
• Amalia Londono Tobon and Hanna Stevens
• Chapter 9: Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) Study
• J. Corey Williams and Hanna Stevens
• Chapter 10: Cognitive Behavioral Therapy, Sertraline, or a Combination in Childhood Anxiety: CAMS
• David Saunders, Jerome Taylor, and Andres Martin
• Chapter 11: Predictors of Suicidal Events: The Treatment of Adolescent Suicide Attempters study (TASA)
• Michael Maksimowski and Zheala Qayyum
• Chapter 12: Cognitive Behavior Therapy, Sertraline, and Their Combination for Children and Adolescents with OCD
• Falisha Gilman and Zheala Qayyum
• Chapter 13: Initial Treatment of Bipolar I Disorder in Children and Adolescents: The TEAM Trial
• Stephanie Ng and Andres Martin
• Chapter 14: The Treatment for Adolescents with Depression Study (TADS)
• Zachary Engler and Zheala Qayyum
• Section 4: Cognitive Disorders: Delirium/Dementia
• Chapter 15: Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease: CATIE-AD
• Adam Mecca and Rajesh R. Tampi
• Chapter 16: Risk of Death with Atypical Antipsychotic Medications for Dementia
• Adam Mecca and Rajesh R. Tampi
• Chapter 17: Treatment of Delirium in Hospitalized AIDS Patients: A Double-Blind Trial of Haloperidol, Chlorpromazine, and Lorazepam
• Amanda Sun and Rajesh R. Tampi
• Chapter 18: Memantine in Patients with Moderate to Severe Alzheimer Disease Already Receiving Donepezil
• Brandon M. Kitay and Rajesh R. Tampi
• Section 5: Epidemiology
• Chapter 19: Global Burden of Mental and Substance Use Disorders
• Stephanie Yarnell and Ellen Edens
• Chapter 20: Prevalence and Severity of Psychiatric Comorbidities: The National Comorbidity Survey Replication (NCS-R)
• Stephanie Yarnell and Ellen Edens
• Section 6: Insomnia
• Chapter 21: Behavioral and/or Pharmacotherapy for Older Patients with Insomnia
• Robert Ross and Rajesh R. Tampi
• Section 7: Major Depressive Disorder
• Chapter 22: Treatment of Depression in Patients with Alcohol or Drug Dependence: A Meta-Analysis
• J. Corey Williams and Gustavo Angarita-Africano
• Chapter 23: Suicidality in Pediatric Patients Treated with Antidepressant Drugs: FDA Meta-analysis
• David Saunders and Michael H. Bloch
• Chapter 24: National Institute of Mental Health (NIMH) Treatment of Depression Collaborative Research Program
• Joseph Taylor and Robert Ostroff
• Chapter 25: Efficacy and Safety of Electroconvulsive Therapy in Depressive Disorders: A Systematic Review and Meta-analysis
• Joseph Taylor and Robert Ostroff
• Chapter 26: Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration
• Michael Maksimowski and Zheala Qayyum
• Chapter 27: Sequenced Treatment Alternatives to Relieve Depression: STAR*D
• Eric Lin and Pochu Ho
• Chapter 28: Cognitive Therapy vs. Medication in the Treatment of Moderate to Severe Depression
• Daniel Barron and Robert Ostroff
• Section 8: Obsessive Compulsive Disorder
• Chapter 29: Exposure and Ritual Prevention, Clomipramine, or Their Combination for Obsessive-Compulsive Disorder
• Brandon M. Kitay and Michael H. Bloch
• Chapter 30: Meta-analysis of the Dose-response relationship of SSRI's in adult patients with Obsessive Compulsive Disorder
• Eunice Yuen and Michael H. Bloch
• Section 9: Personality Disorders
• Chapter 31: Psychotherapy for Borderline Personality Disorder: A Multiwave Study
• David Grunwald, Erica Robinson, and Sarah Fineberg
• Chapter 32: Dialectical Behavior Therapy vs. Community Treatment by Experts for Reducing Suicidal Behaviors Among Patients with Borderline Personality Disorder
• David Saunders, Erica Robinson, and Sarah Fineberg
• Chapter 33: Ten-Year Course of Borderline Personality Disorder: The Collaborative Longitudinal Personality Disorders Study
• Kevin Johnson, Erica Robinson, and Sarah Fineberg
• Section 10: Psychiatry in Primary Care
• Chapter 34: Depressive Symptoms and Health-Related Quality of Life: The Heart and Soul Study
• Amalia Londono Tobon and Catherine Chiles
• Chapter 35: The Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) Trial
• Nikhil Gupta and Catherine Chiles
• Section 11: Women's Mental Health
• Chapter 36: Buprenorphine vs. Methadone During Pregnancy: The MOTHER Trial
• Rachel Wurmser and Kirstin Wilkins
• Section 12: Schizophrenia
• Chapter 37: QTc-Interval Abnormalities and Psychotropic Drug Therapy in Psychiatric Patients
• Amanda Sun and Vinod H. Srihari
• Chapter 38: Tardive Dyskinesia with Atypical vs. Conventional Antipsychotic Medications
• Emma Lo and Cenk Tek
• Chapter 39: Effectiveness of Antipsychotics in the Treatment of Schizophrenia: CATIE Phase 1
• Chadrick Lane and Mohini Ranganathan
• Chapter 40: Clozapine for Treatment-Resistant Schizophrenia
• Chadrick Lane and Vinod H. Srihari
• Chapter 41: Effectiveness of clozapine vs. other atypical antipsychotics: Clinical Antipsychotic Trials for Interventions Effectiveness (CATIE)
• Eunice Yuen and Cenk Tek
• Chapter 42: Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death
• Hamilton Hicks and Cenk Tek
• Chapter 43: Switching Antipsychotics to Reduce Metabolic Risk: The CAMP Trial
• Eric Lin and John Cahill
• Chapter 44: Cost Utility of Atypical Antipsychotics: CUtLASS-1
• Nikhil Gupta and John Cahill
• Chapter 45: North American Prodrome Longitudinal Study
• Nikhil Gupta and Vinod H. Srihari
• Chapter 46: Clozapine for Suicidality in Schizophrenia: The International Suicide Prevention Trial (InterSePT)
• Daniel Barron and Noah Capurso
• Chapter 47: A Cohort Study of Oral and Depot Antipsychotics After First Hospitalization for Schizophrenia
• Stephanie Ng and Cenk Tek
• Section 13: Substance Use Disorders
• Chapter 48: Methadone Maintenance vs. Detoxification and Psychosocial Treatment for Opioid Dependence: The M180 Study
• Hamilton Hicks and Srinivas Muvvala
• Chapter 49: Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence: The COMBINE Study
• Kevin Johnson and Srinivas Muvvala
• Chapter 50: Levomethadyl acetate vs. Buprenorphine vs. Methadone for Opioid Dependence
• Robert Ross and Brian Fuehrlein